Form 4: Scholar Rock Holding Corp: Officer Tracey Sacco Reports Stock and Option Transactions

Tracey Sacco, Chief Commercial Officer of Scholar Rock Holding Corp, reports acquisition of restricted stock units and stock options, along with adjustments to direct and indirect ownership of common stock.

Summary

• On March 10, 2025, Tracey Sacco, Chief Commercial Officer of Scholar Rock Holding Corp, filed a Form 4 detailing changes in beneficial ownership.
• Sacco acquired 27,855 restricted stock units (RSUs), each representing a contingent right to receive one share of the Issuer's common stock upon vesting.
• These RSUs vest in four annual installments starting February 15, 2026, contingent upon continued service with the Issuer.
• Sacco also acquired options to purchase 37,145 shares of common stock at an exercise price of $35.15.
• These options vest in sixteen quarterly installments starting April 1, 2025, also contingent upon continued service.
• Following these transactions, Sacco directly owns 37,145 derivative securities and beneficially owns 73,250 shares of common stock, including 8,431 shares of common stock and 64,819 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects standard executive compensation practices and insider transactions. There are no explicit positive or negative indicators about the company's performance.

Positives

• The acquisition of RSUs and stock options aligns the officer's interests with the long-term performance of the company.
• The vesting schedules of the RSUs and options incentivize continued service with the company.

Future Outlook

The vesting schedules of the RSUs and stock options suggest an expectation of continued service and contribution from the reporting person.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent.
• Vesting schedules are typically structured to align executive incentives with long-term shareholder value creation.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize similar equity-based compensation plans for their executives.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by slightly diluting equity over time as options are exercised and RSUs vest.
• Employees may view the equity grants as a positive sign of the company's commitment to its employees.

Key Dates